Heart failure (HF) has proven to be a major burden on the health system. The continuing
prevalence of the condition and its rising associated costs and care, has amplified the need …

Opinion statement Investigation of the complex biochemical pathways that underlie heart
failure (HF) has led to the recognition of multiple molecular markers that may help to …

Heart failure (HF) is a significant cause of morbidity and mortality worldwide. Circulating
biomarkers reflecting pathophysiological pathways involved in HF development and …

Risk prediction in patients admitted with acute decompensated heart failure (ADHF) remains
a challenge. Biomarkers may improve risk prediction, which in turn may help to better inform …

Heart failure (HF) results from the impaired ability of heart to fill or pump out blood. HF is a
common health problem with a multitude of causes and affects~ 30 million people …

Hospitalization for decompensated heart failure (HF) is associated with extraordinarily high
rates of morbidity and mortality. Despite its high prevalence its pathophysiologic …

Cardiac biomarkers play an important role in and provide better pathophysiological
understanding of chronic heart failure (CHF). Natriuretic peptides, especially B-type …

Despite the enhanced knowledge of the pathophysiology of heart failure (HF), it still remains
a serious syndrome with substantial morbidity, mortality, and frequent hospitalizations …

Opinion statement Biomarkers, especially natriuretic peptides such as B-type natriuretic
peptide (BNP) and N-terminal-proBNP (NT-proBNP), are a valuable addition to standard …

Biomarkers have become an increasingly important tool in clinical practice, helping to
improve patient care. In heart failure (HF), brain natriuretic peptide and N-terminal …